NYSE:ABBV - AbbVie Stock Price, Forecast & News

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie announced a -- dividend on Friday, November 1st. Shareholders of record on Wednesday, January 15th will be given a dividend of $1.18 per share on Friday, February 14th. This represents a yield of 5.93%. The ex-dividend date is Tuesday, January 14th. This is a positive change from AbbVie's previous -- dividend of $1.07. View AbbVie's Dividend History.

AbbVie announced that its board has initiated a share repurchase plan on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 3.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings results on Friday, November, 1st. The company reported $2.33 earnings per share for the quarter, beating the consensus estimate of $2.29 by $0.04. The company earned $8.48 billion during the quarter, compared to analyst estimates of $8.37 billion. AbbVie had a negative return on equity of 155.96% and a net margin of 9.90%. The firm's quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.14 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for AbbVie.

AbbVie will be holding an earnings conference call on Friday, February 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie updated its FY19 earnings guidance on Friday, November, 1st. The company provided earnings per share (EPS) guidance of $8.90-8.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.90.

13 Wall Street analysts have issued 1 year price targets for AbbVie's shares. Their forecasts range from $66.61 to $98.00. On average, they anticipate AbbVie's share price to reach $86.33 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for AbbVie.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Media coverage about ABBV stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AbbVie earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional investors include New York State Teachers Retirement System (0.15%), Artemis Investment Management LLP (0.07%), Hamlin Capital Management LLC (0.06%), Strs Ohio (0.06%), State of Michigan Retirement System (0.06%) and Candriam Luxembourg S.C.A. (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Galibier Capital Management Ltd., Ambassador Advisors LLC, Candriam Luxembourg S.C.A., Commerzbank Aktiengesellschaft FI, Meag Munich Ergo Kapitalanlagegesellschaft MBH, OLD National Bancorp IN, Strs Ohio and TIAA FSB. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Laura J Schumacher and Timothy J Richmond. View Insider Buying and Selling for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Zurcher Kantonalbank Zurich Cantonalbank, Artemis Investment Management LLP, CHURCHILL MANAGEMENT Corp, State of Michigan Retirement System, 6 Meridian, First American Bank and Rhenman & Partners Asset Management AB. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $83.54.

AbbVie has a market capitalization of $123.54 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.